Abstract 5117: An automated 5-plex fluorescent immunohistochemistry enabled characterization of PD-L1 expression and tumor infiltrating immune cells in lung and bladder cancer specimens

2016 ◽  
Author(s):  
Wenjun Zhang ◽  
Antony Hubbard ◽  
Adriana Racolta ◽  
Nick Cummins ◽  
Mehrnoush Khojasteh ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Immune Cells ◽  
Fluorescent Immunohistochemistry

scholarly journals Characterization of Oral Squamous Cell Carcinoma Associated Inflammation: A Pilot Study

2021 ◽  
Vol 2 ◽  
Author(s):  
Catherine Laliberté ◽  
Nicole Ng ◽  
Denise Eymael ◽  
Kevin Higgins ◽  
Aiman Ali ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Immune Cells ◽  
Tumor Development ◽  
Tissue Analysis ◽  
Fluorescent Immunohistochemistry ◽  
Pro Inflammatory Cytokines

Background: Oral squamous cell carcinoma (OSCC) is a devastating disease that is usually associated with a dense associated inflammatory infiltrate. Characterizing tumor-associated inflammation is critical to understand the pathogenies of tumor development and progression.Methods: We have tested a protocol to analyze tissue and salivary immune cells and mediators of 37 patients with OSCC at different stages and compared to eight chronic periodontitis patients and 24 healthy controls. Tissue analysis was based on fluorescent immunohistochemistry (FIHC) and inflammatory mediators were analyzed using a Luminex-based 30-Plex panel. Immune cells were analyzed using multichannel flow cytometry including CD45, CD66b, CD3, CD4, CD8, CD25, CD56, CD68, CD138, PD-1, and PD-L1.Results: We show an increase in OSCC-associated inflammation characterized by increased pro-inflammatory cytokines including IL-6, IL-8, TNFα, and GMCSF and increased salivary immune cells.Conclusion: We described a new method to analyze salivary inflammatory markers that can be used in future studies to monitor disease progression and prognosis.

Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study

2020 ◽  
Vol 38 (7) ◽  
pp. 615-621
Author(s):  
Juan Chipollini ◽  
Justin R. Wright ◽  
Hephzibah Nwanosike ◽  
Carole Y. Kepler ◽  
Ken Batai ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Feasibility Study ◽  
Single Institution ◽  
Urinary Microbiome

scholarly journals Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients

Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1796
Author(s):  
Markus Eckstein ◽  
Verena Lieb ◽  
Rudolf Jung ◽  
Danijel Sikic ◽  
Katrin Weigelt ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Factor ◽  
Tumor Cells ◽  
Immune Cells ◽  
Potential Candidate ◽  
Poor Prognostic Factor ◽  
Risk Of Death ◽  
Increased Risk ◽  
Muscle Invasive ◽  
Disease Specific

Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candidate marker that meets these criteria is progranulin (GP88), which is expressed separately in TCs and ICs. We analyzed GP88 expression by immunohistochemistry (IHC) in 196 muscle-invasive BCa samples using a tissue microarray. The immunoreactive score for GP88 staining in TCs and the percentage of GP88-positive ICs was determined. An easy cutoff for the staining status of TCs (positive vs. negative) and ICs (0% vs. >0%) and, more generally, negative vs. positive GP88 staining could be applied. We detected 93 patients (47.4%) and 92 patients (46.9%) with GP88-positive TCs or ICs, respectively. The IHC results were correlated with clinicopathological and survival data. Positive GP88 staining in TCs appeared to be an independent poor prognostic factor for disease-specific survival (DSS) (RR (relative risk) = 1.74; p = 0.009) and recurrence-free survival (RFS) (RR = 1.92; p = 0.002). In contrast, negative GP88 staining in ICs was an independent negative predictor for overall survival (OS) (RR = 2.18; p < 0.001), DSS (RR = 2.84; p < 0.001) and RFS (RR = 2.91; p < 0.001) in multivariate Cox’s regression analysis. When combining GP88 staining in TCs and ICs, a specific combination of GP88-positive TCs and GP88-negative ICs was associated with a 2.54-fold increased risk of death, a 4.21-fold increased risk of disease-specific death and a 4.81-fold increased risk of recurrence compared to GP88-negative TCs and GP88-positive ICs. In summary, GP88 positivity in TCs is a negative prognostic factor for DSS and RFS. In addition, GP88 positivity can mark ICs that are associated with a good prognosis (OS, DSS and RFS). The combination of GP88 staining in TCs and ICs appears to be a significant independent prognostic biomarker in muscle-invasive BCa.

Clinical characterization of radiation-associated muscle-invasive bladder cancer

Urology ◽  
2021 ◽  
Author(s):  
Sybil T. Sha ◽  
Edward Christopher Dee ◽  
Matthew Mossanen ◽  
Brandon A. Mahal ◽  
Cierra Zaslowe-Dude ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Cell Therapies in Bladder Cancer Management

2021 ◽  
Vol 22 (6) ◽  
pp. 2818
Author(s):  
Lucia Morales ◽  
Jesús M. Paramio
Keyword(s):  
Bladder Cancer ◽  
Immune Cells ◽  
Therapeutic Option ◽  
Immune Checkpoint Blockade ◽  
Special Focus ◽  
Challenging Problem ◽  
Cell Therapies ◽  
Cancer Management ◽  
Hematological Cancers ◽  
High Incidence

Currently, bladder cancer (BC) represents a challenging problem in the field of Oncology. The high incidence, prevalence, and progression of BC have led to the exploration of new avenues in its management, in particular in advanced metastatic stages. The recent inclusion of immune checkpoint blockade inhibitors as a therapeutic option for BC represents an unprecedented advance in BC management. However, although some patients show durable responses, the fraction of patients showing benefit is still limited. Notwithstanding, cell-based therapies, initially developed for the management of hematological cancers by infusing immune or trained immune cells or after the engineering of chimeric antigen receptor (CAR) expressing cells, are promising tools to control, or even cure, solid tumors. In this review, we summarize recent cell-based immunotherapy studies, with a special focus on BC.

Characterization of the tumor-infiltrating immune repertoire in Muscle Invasive Bladder Cancer

2021 ◽  
Vol 79 ◽  
pp. S641
Author(s):  
R. Benítez Dorta ◽  
K. Yu ◽  
M. Sirota ◽  
N. Malats ◽  
S. Pineda
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Immune Repertoire ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Characterization of the immunomodulatory effect in vitro of microvesicles isolated from mesenchymal stromal cells on immune cells

2013 ◽  
Vol 41 (8) ◽  
pp. S64
Author(s):  
Antonella Conforti ◽  
Marco Scarsella ◽  
Ezio Giorda ◽  
Simone Biagini ◽  
Nadia Starc ◽  
...  
Keyword(s):  
Mesenchymal Stromal Cells ◽  
Immune Cells ◽  
Stromal Cells ◽  
Immunomodulatory Effect

scholarly journals Comprehensive Analysis of CPA4 as a Poor Prognostic Biomarker Correlated with Immune Cells Infiltration in Bladder Cancer

Biology ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1143
Author(s):  
Chengcheng Wei ◽  
Yuancheng Zhou ◽  
Qi Xiong ◽  
Ming Xiong ◽  
Yaxin Hou ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
T Cell ◽  
Immune Cells ◽  
Prognostic Significance ◽  
Gene Set Enrichment Analysis ◽  
Marker Genes ◽  
Gene Marker ◽  
Normal Tissues ◽  
Kaplan Meier ◽  
Diagnostic Potential

Carboxypeptidase A4 (CPA4) has shown the potential to be a biomarker in the early diagnosis of certain cancers. However, no previous research has linked CPA4 to therapeutic or prognostic significance in bladder cancer. Using data from The Cancer Genome Atlas (TCGA) database, we set out to determine the full extent of the link between CPA4 and BLCA. We further analyzed the interacting proteins of CPA4 and infiltrated immune cells via the TIMER2, STRING, and GEPIA2 databases. The expression of CPA4 in tumor and normal tissues was compared using the TCGA + GETx database. The connection between CPA4 expression and clinicopathologic characteristics and overall survival (OS) was investigated using multivariate methods and Kaplan–Meier survival curves. The potential functions and pathways were investigated via gene set enrichment analysis. Furthermore, we analyze the associations between CPA4 expression and infiltrated immune cells with their respective gene marker sets using the ssGSEA, TIMER2, and GEPIA2 databases. Compared with matching normal tissues, human CPA4 was found to be substantially expressed. We confirmed that the overexpression of CPA4 is linked with shorter OS, DSF(Disease-specific survival), PFI(Progression-free interval), and increased diagnostic potential using Kaplan–Meier and ROC analysis. The expression of CPA4 is related to T-bet, IL12RB2, CTLA4, and LAG3, among which T-bet and IL12RB2 are Th1 marker genes while CTLA4 and LAG3 are related to T cell exhaustion, which may be used to guide the application of checkpoint blockade and the adoption of T cell transfer therapy.

Sign in / Sign up

Export Citation Format

Share Document